Giant Cell Tumor of Bone Clinical Trial
Official title:
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone: A Prospective Randomized Controlled Trial
The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor.
The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate (BP-loaded PMMA bone cement) as a surgical adjuvant can decrease the local recurrence rate of giant cell tumor (GCT) of bone. The investigators will evaluate whether bisphosphonate as a surgical adjuvant improves secondary outcomes, such as pain, function, fever, or wound complications. The hypothesis is that the local administration of bisphosphonate will decrease the recurrence rate of GCT compared to traditional aggressive intralesional curettage. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Active, not recruiting |
NCT04255576 -
Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone
|
Phase 1/Phase 2 | |
Completed |
NCT03301857 -
Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
|
Phase 4 | |
Completed |
NCT05402865 -
A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone
|
||
Completed |
NCT00464620 -
Trial of Dasatinib in Advanced Sarcomas
|
Phase 2 | |
Recruiting |
NCT03259152 -
Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone
|
Phase 3 | |
Recruiting |
NCT05595603 -
Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage
|
Phase 2 | |
Not yet recruiting |
NCT03358212 -
Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China
|
N/A | |
Completed |
NCT04002817 -
Giant Cell Tumor of the Bone in Young Patients
|
||
Completed |
NCT00396279 -
Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone
|
Phase 2 | |
Terminated |
NCT00889590 -
Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)
|
Phase 2 | |
Recruiting |
NCT04586660 -
Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
|
Phase 4 | |
Active, not recruiting |
NCT03449108 -
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
|
Phase 2 | |
Not yet recruiting |
NCT05813665 -
A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone
|
Phase 3 | |
Completed |
NCT02996734 -
Giant Cell Tumor of the Extremities Treated With Surgery and/or Medical Treatment
|
N/A |